New resorbable magnesium scaffold promising for coronary lesions: BIOMAG-1 first-in-human study

The findings were published in EuroIntervention and presented at the 2023 European Atherosclerosis Society (EAS) Congress.

"The third-generation bioresorbable magnesium scaffold is clinically effective and safe, making it a possible alternative to drug-eluting stents (DES)," Michael Haude, Medical Clinic I, Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Neuss, Germany; and colleagues wrote in their study. On optical coherence tomography, investigators saw a significant decrease in the total lipid area and a significant increase in fibrous tissue in this first-in-human study with the newest-generation bioresorbable scaffold.

The sirolimus-eluting scaffold is made from a proprietary magnesium alloy and has been on the European market in a different form for many years. However, recently it has been redesigned to decrease the strut thickness while increasing the amount of radial force, but resorbing entirely by one year.

DREAMS 3G, the third-generation coronary sirolimus-eluting magnesium scaffold, is a further development of the DREAMS 2G (commercial name Magmaris), which aims to provide performance outcomes comparable to DES. The researchers aimed to assess the performance and safety of this new-generation scaffold in the BIOMAG-I study.

The study was designed as a multicentre, prospective, first-in-human study with clinical and imaging follow-ups scheduled at 6 and 12 months. The clinical follow-up will continue for five years. The researchers enrolled 116 patients (mean age 61 years; 77.8% male) with 117 lesions, with documented silent ischemia, stable or unstable angina, or hemodynamically stable NSTEMI. Most lesions were classified as type B2/C, and just 2.6% were considered moderately or severely calcified.

The study led to the following findings:

• At 12 months, after completion of resorption, in-scaffold late lumen loss was 0.24±0.36 mm.
• The minimum lumen area was 4.95±2.24 mm² by intravascular ultrasound and 4.68±2.32 mm² by optical coherence tomography.
• Three target lesion failures (2.6%) were reported, all clinically driven target lesion revascularisations.
• Cardiac death, target vessel myocardial infarction and definite or probable scaffold thrombosis were absent.

"Data at the end of the resorption period of DREAMS 3G revealed that the third-generation bioresorbable magnesium scaffold is clinically effective and effective, making it a possible alternative to DES," the researchers concluded.

Reference:

The study, "A new resorbable magnesium scaffold for de novo coronary lesions, the DREAMS 3G: one-year results of the BIOMAG-1 first-in-human study," was published in EuroIntervention.

DOI: 10.4244/EIJ-D-23-00326